In the aftermath of the U.S. Supreme Court’s landmark biosimilars ruling, Amgen Inc. and Sandoz Inc. clashed late Monday over whether biosimilar makers can be punished for not divulging their approval applications to innovator rivals.
In the aftermath of the U.S. Supreme Court’s landmark biosimilars ruling, Amgen Inc. and Sandoz Inc. clashed late Monday over whether biosimilar makers can be punished for not divulging their approval applications to innovator rivals.
